Abstract:In chronic infections and cancer, exhausted CD8 T cells exhibit heterogeneous subpopulations. TCF1+PD-1+ progenitor exhausted CD8 T cells (Tpex) can self-renew and give rise to Tim-3+PD-1+ terminally differentiated CD8 T cells that retain their effector functions. Tpex cells are thus essential to maintaining a pool of antigen-specific CD8 T cells during persistent antigenic stimulation, and only they respond to PD-1-targeted therapy. Despite their potential as a crucial therapeutic target for immune interventions, the mechanisms controlling the maintenance of virus-specific Tpex cells remain to be determined. We observed approximately 10-fold fewer Tpex cells in the spleens of mice chronically infected with lymphocytic choriomeningitis virus (LCMV) one-year post-infection (p.i.) than at three months p.i. Similar to memory CD8 T cells, Tpex cells have been found to undergo self-renewal in the lymphoid organs, prominently the bone marrow, during chronic LCMV infection. Furthermore, ex vivo treatment with IL-15 preferentially induced the proliferation of Tpex cells rather than the terminally differentiated subsets. Interestingly, single-cell RNA sequencing analysis of LCMV-specific exhausted CD8 T cells after ex vivo IL-15 treatment compared with those before treatment revealed increased expression of ribosome-related genes and decreased expression of genes associated with the TCR signaling pathway and apoptosis in both Tpex and Ttex subsets. The exogenous administration of IL-15 to chronically LCMV-infected mice also significantly increased self-renewal of Tpex cells in the spleen and bone marrow. In addition, we assessed the responsiveness of CD8 tumor-infiltrating lymphocytes (TILs) from renal cell carcinoma patients to IL-15. Similar to the data we obtained from chronic viral infection in mice, the expansion of the Tpex subset of PD-1+ CD8 TILs upon ex vivo IL-15 treatment was significantly higher than that of the terminally differentiated subset. These results show that IL-15 could promote self-renewal of Tpex cells, which has important therapeutic implications.

Antitumor progenitor exhausted CD8 + T cells are sustained by TCR engagement

Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells

Potential mechanisms of cancer stem-like progenitor T-cell bio-behaviours

Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response

PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells

TCF‐1 maintains CD8+ T cell stemness in tumor microenvironment

Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms

IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation

Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site

Antigen presentation by tumor-associated macrophages drives tumor-infiltrating T cells from a progenitor exhaustion state to terminal exhaustion

Developmental relationships of four exhausted CD8 T cell subsets reveals underlying transcriptional and epigenetic control mechanisms

Reinvigorated exhausted T cells exhibit distinct features within 24 hours after PD-1 therapy

Precursor exhausted CD8+T cells in colorectal cancer tissues associated with patient's survival and immunotherapy responsiveness

Precursor exhausted T cells: key to successful immunotherapy?

Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

The Primordial Differentiation of Tumor-Specific Memory CD8+ T Cells As Bona Fide Responders to PD-1/PD-L1 Blockade in Draining Lymph Nodes.

Dendritic cells maintain anti-tumor immunity by positioning CD8 skin-resident memory T cells